



Feb. 29, 2012.

For Immediate Release

***TeraBAT, Inc.*, Medical Device Startup, Licenses Technology from the University of Massachusetts Amherst**

LONGMONT, CO. – *TeraBAT, Inc.*, a medical diagnostic startup company based in Longmont, Colo., has been granted an exclusive global license to use terawaves technology owned by the University of Massachusetts Amherst.

The patent-pending technology employs electromagnetic waves in the terahertz range to identify molecules in gases. *TeraBAT, Inc.* is working to commercialize the technology to rapidly detect biomarkers in exhaled breath that are indicators of acute and chronic diseases. In a hospital or clinic, a healthcare provider would be able to initiate treatment without delay and continuously monitor the disease's state from the biomolecules present in the patient's breath. The company plans that the non-invasive point-of-care platform will replace today's laboratory based-diagnostics with more direct tests beside the patient, resulting in positive health and economic outcomes.

TeraBAT, Inc. was founded by former UMass Amherst researcher Eyal Gerecht, Ph.D. who developed the terawaves technology with researchers from the National Institute of Standards and Technology (NIST). Gerecht received his doctorate from UMass Amherst and has worked at NIST for over 10 years developing a number of terahertz technologies for imaging and spectroscopy for homeland security and biomedical applications.

"It is very rewarding that, after years of laboratory research, we can launch the commercialization stage for this technology and begin to make a real impact in everyday life," said Gerecht.

William Rosenberg, executive director of the UMass Office of Commercial Ventures and Intellectual Property, says, "Gerecht's new technique opens the door to a wide range of quick and inexpensive diagnostic and monitoring applications in several fields and we are looking forward to *TeraBAT's* efforts to develop this approach and bring its benefits to the public."

About *TeraBAT, Inc.*:

TeraBAT, Inc. is a Colorado-based company developing a disruptive detection platform based on terawaves technologies that will revolutionize disease diagnosis and patient care. Its novel, real time detection platform will be able to identify biomolecules present in exhaled breath that are indicative of a disease state. Rapid diagnosis of both chronic and acute disease states via breath analysis will allow immediate and correct patient treatment and care.

About UMass Amherst:

Founded in 1863, the University of Massachusetts Amherst is a distinguished national research university and the flagship of the five-campus UMass system, enrolling more than 27,500 students in 94 undergraduate more than 70 graduate-level programs. UMass Amherst had \$137.4 million in sponsored research in fiscal 2009 and has an economic impact of \$1.43 billion in Massachusetts.